



**СРПСКИ АРХИВ**  
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО  
**SERBIAN ARCHIVES**  
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: [office@srpskiarhiv.rs](mailto:office@srpskiarhiv.rs), Web address: [www.srpskiarhiv.rs](http://www.srpskiarhiv.rs)

Paper Accepted\*

ISSN Online 2406-0895

**Case Report / Приказ болесника**

Ana Milenković<sup>1</sup>, Miroslav Ilić<sup>1,2,\*</sup>, Jovan Javorac<sup>1,2,3</sup>, Nevena Savić<sup>1</sup>, Nensi Lalić<sup>1,2</sup>

**Lymphangiomyomatosis and Langerhans cell histiocytosis –  
two case reports from our practice**

Лимфангиолејомиоматоза и Лангерхансова хистиоцитоза –  
два приказа болесника из наше праксе

<sup>1</sup>Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia;

<sup>2</sup>University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia;

<sup>3</sup>College of Vocational Studies for the Education of Preschool Teachers and Sport Trainers, Subotica, Serbia

**Received: December 3, 2021**

**Revised: March 22, 2022**

**Accepted: March 25, 2022**

**Online First: March 29, 2022**

**DOI: <https://doi.org/10.2298/SARH211203034M>**

\***Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. *Srp Arh Celok Lek*. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

**\*Correspondence to:**

Miroslav ILIĆ

University of Novi Sad, Faculty of Medicine, Institute for Pulmonary Diseases of Vojvodina, 4 Institutski put, Sremska Kamenica 21204, Serbia

E mail: [miroslav.ilic@mf.uns.ac.rs](mailto:miroslav.ilic@mf.uns.ac.rs)

## Lymphangiomyomatosis and Langerhans cell histiocytosis – two case reports from our practice

### Лимфангиолејомиоматоза и Лангерхансова хистиоцитоза – два приказа болесника из наше праксе

#### SUMMARY

**Introduction** Lymphangiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH) are the most common pulmonary cystic diseases. Although they differ in pathogenesis, they share several features. The aim of this paper is to present the similarities and differences between these diseases, as well as to describe two cases from our practice.

**Outlines of cases** The patient with LAM (43 y.) has pulmonary changes detected during regular examination within the underlying disease – tuberous sclerosis. Four years after starting therapy with everolimus she is still respiratory asymptomatic, a slight radiological deterioration of cystic changes is registered, the diffusion capacity is declining (for 12%).

The second patient (23 y.) was admitted due to bilateral radiological lung changes and symptoms in the form of dry cough, quick fatigue and chest pain. Pathohistological examination of the transbronchial biopsy showed numerous large-core histiocytes, immunohistochemically positive for CD1a and S100, so it has been concluded that it is Langerhans cell histiocytosis. Cessation of smoking was advised. The follow-up examinations show withdrawal of symptoms and an orderly finding of lung function, chest HRCT indicates slight regression of changes. In the meantime, the patient gave birth to a healthy child, the pregnancy and prenatal period went smoothly.

**Conclusion** These diseases are extremely rare and in cooperation with other specialties should be distinguished from diseases that mimic lung cysts.

**Keywords:** lymphangiomyomatosis; pulmonary Langerhans cell histiocytosis; cystic lung disease

#### САЖЕТАК

**Увод** Лимфангиолејомиоматоза (ЛИАМ) и плућна Лангерхансова хистиоцитоза (ПЛЦХ) су две најчешће плућне цистичне болести. Према се разликују у патогенези, имају неколико заједничких карактеристика. Циљ рада је био описати сличности и разлике између ових болести, као и приказати два случаја из наше праксе.

**Прикази болесника** Пацијенткиња са ЛИАМ (43 г.) су плућне промене откривене током редовних контрола основне болести- туберозне склерозе. Након четири године лечења еверолимуомом она је и даље респираторно асимптоматична, са благом радиолошком прогресијом цистичних промена, и падом капацитета диузије (за 12%).

Друга пацијенткиња (23 г.) је хоспитализована због обостраних плућних промена и симптома у виду сувог кашља, убрзаног замарања и болова у грудном кошу.

Патохистолошким прегледом трансbronхијалне биопсије уочени су бројни хистиоцити, имунохистохемијски позитивни на CD1a и S100, те је закључено да се ради о Лангерхансовој хистиоцитози. Саветован је престанак пушења. На контролним прегледима болесница је била асимптоматична, налази плућне функције уредни, ХРЦТ грудног коша указује на благу регресију промена. У међувремену пацијенткиња је родила здраво дете, трудноћа и перинатално доба су протекли уредно.

**Закључак** Ове болести су изузетно ретке и у сарадњи са другим специјалностима треба их разликовати од болести које имитирају плућне цисте.

**Кључне речи:** лимфангиолејомиоматоза; плућна Лангерхансова хистиоцитоза; цистичне плућне болести

## INTRODUCTION

Diffuse cystic lung diseases are a group of disorders of different pathophysiological mechanism of occurrence, which is characterized by the presence of multiple lung cysts [1]. There are conditions that mimic lung cysts, both in clinical and radiological terms, and these are emphysema, bronchiectasis, cavitation, honeycombing, localized pneumothorax [2]. Individual cysts in the lungs may be present in healthy individuals, as well as a result of aging,

previous infections or trauma. In the past decade, owing to the development of high-resolution computed tomography (HRCT), level of knowledge about these diseases has increased and disease evaluation is performed based on the radiological appearance of cysts (shape, size, wall thickness and distribution) [1, 3].

Lymphangiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH) are the most common pulmonary cystic diseases. Although they differ in pathogenesis, they share several features. Both diseases act as neoplastic disorders, have cystic radiological pattern, affect young people in generative period, and can have extrapulmonary involvement.

The aim of the paper is to present the similarities and differences between these diseases as well as to describe two cases from our practice.

## **REPORTS OF CASES**

### **The patient with lymphangiomyomatosis**

Female patient (43 y.) was referred to the Institute of Pulmonary Diseases of Vojvodina (IPDV) in 2016 by a competent neurologist to clarify the etiology of bilateral diffuse pulmonary changes, detected during regular systematic physical examination within the underlying disease - tuberous sclerosis, which was diagnosed in her 4th month of life. Within her underlying disease, the patient has occasional epileptic seizures of the petit mal type, mild mental retardation, changes in the skin of the face and torso, previously ultrasound-verified tumor altered structures of the kidneys and uterus (myomas).

Upon admission, the patient is asymptomatic; auscultatory finding is normal. X-ray of the chest shows a without pathological changes over the lungs. HRCT verified bilateral and diffusely increased density of the lung parenchyma, which showed smooth thickening of interlobular septa and a large number of clearly demarcated, randomly distributed hypodense (cystic) smooth-walled lesions of various shapes and diameters (up to 16 mm in diameter) (Figure 1). The pulmonary gas exchange is preserved at rest, while during exercise of two floors oxygen drops by 1.3 kPa. The spirometry finding is normal. During 6-minute walk test (6MWT) the patient crossed 420m (57%). Mild pulmonary hypertension (RVSP 35mmHg)

is verified by echocardiography (ECHO). Based on the clinical and radiological findings, the patient was diagnosed with LAM within the tuberous sclerosis complex. The patient started using everolimus (5mg/day) in agreement with a neurologist and immunologist.

The patient reported four years after the first examination (she didn't come to the advised annual check-ups on her own initiative). She denied respiratory problems, auscultatory finding is normal. HRCT indicates a discrete increase in the number of multifocal thin-walled cystic changes (Figure 2). The spirometric finding is normal, the diffusion capacity is declining compared to the first examination (Table 1). The ECHO finding is stationary. It was continued the use of everolimus.

### **The patient with Langerhans cell histiocytosis**

Patient (23 y.) was admitted to the IPDV in 2018 due to bilateral radiological lung changes and symptoms (dry cough, chest pain and quick fatigue), that appeared two weeks before admission. She is a smoker (5 packs/year), without comorbidities.

The X-ray of the chest verifies reticular changes in the upper and middle lung fields on both sides. Chest HRCT indicates bilateral diffuse, more pronounced in the upper and middle parts, thin-walled cystic lesions of various sizes, up to 15 mm in size (Figure 3). Spiroplethysmographic finding indicates a slightly reduced diffusion capacity (64%). The gas exchange is normal. Pulmonary hypertension (RVSP 43mmHg) is registered ECHO. Pathohistological examination of the transbronchial biopsy showed numerous large-core histiocytes, immunohistochemically positive for CD1a and S100. It has been concluded that it is Langerhans cell histiocytosis and additional examination (ultrasound and CT of the abdomen, endocrinological examination) ruled out systemic spread of the disease. The therapy included advice on the cessation of smoking, which the patient did.

The 6-month follow-up examinations show a good general condition of the patient and an orderly finding of lung function. In the meantime, the patient gave birth to a healthy boy, the pregnancy and perinatal period went smoothly. Chest HRCT three years after diagnosis (Figure 4) indicates slight regression of bilateral cystic changes. ECHO shows an improvement,

RVSP is within the reference limits. Diffusion capacity was not done due to the COVID19 pandemic (IPDV was in the COVID system).

This paper was approved by the Ethics Board of the Institute for Pulmonary Diseases of Vojvodina.

## DISCUSSION

Pulmonary LAM is a disease involving the proliferation of smooth muscle cells of the blood and lymph vessels of the pulmonary interstitium, which leads to the formation of thin-walled cysts, pulmonary hemorrhage and the involvement of lymph nodes can lead to chylous pleural effusions [4].

PLCH is a disease of former or current smokers, where cigarette smoking triggers abnormal proliferation and migration of dendritic cells, then activation of the immune system, which all together leads to the formation of peribronchiolar nodules and later lung cysts [1]. These two diseases are reclassified from interstitial diseases into tumors -LAM belongs to PEComa tumors (perivascular epithelial tumors) which are classified as low-grade connective tissue neoplasms, and PLCH is classified as a bone marrow derived dendritic cell tumor according to the World Health Organization [4].

Both diseases can occur in isolated or systemic form. LAM exists in a sporadic form (s-LAM) or within the tuberous sclerosis complex (TSC/LAM). Likewise, Langerhans histiocytosis may have its own isolated-pulmonary form (PLCH), or multisystem form (MS-LCH) [1].

These diseases are extremely rare. The annual incidence of PLCH is 2.2/1 million, while the incidence of LAM is 1-7/1 million inhabitants [3]. There are no official data for Serbia, neither for region [5,6]. PLCH is equally represented by sexes, s-LAM occurs only in women, small percentage (13%) men with tuberous sclerosis (TSC) will develop LAM [4,7]. Age at diagnosis is similar for both diseases (32-35 years) [4,7]. Smoking is 90-100% present in PLCH, while LAM occurs mainly in non-smokers [4,7]. Our patients were females in

generative period (PLCH patient was 23, LAM patient was 43 years old). The patient with PLCH was a smoker; patient with LAM was a non-smoker.

In clinical terms, both diseases may be asymptomatic when detected as an incidental finding, or may be accompanied by nonspecific symptoms (cough and/or difficulty breathing), while acute shortness of breath is a consequence of pneumothorax [3]. In our cases patient with LAM was asymptomatic, previously diagnosed with TSC which urged further diagnosis. The patient with PLCH had symptoms like dry cough, chest pain and fatigue.

The radiograph in both diseases shows the changes primarily in the upper and middle thirds of the lungs, in the form of discrete cystic changes of the interstitium. HRCT is essential in diagnosing and monitoring both diseases. According to the criteria of the European Respiratory Society (ERS) in the diagnostic algorithm of LAM, the finding of HRCT with the data on previously proven tuberous sclerosis may be sufficient to give a diagnosis, as was the case with our patient. HRCT findings in LAM describe multiple (more than 10), diffusely distributed, thin-walled (up to 2mm), round, clearly demarcated, air-filled cysts with preserved or increased lung volume without other interstitial damage except for the possible presence of micronodular epithelial hyperplasia in tuberous sclerosis [7].

The HRCT findings of PLCH patients depend on the stage of the disease. In the early phase of the disease, it is dominated by centrilobular nodules, 1-10 mm in diameter. In the later stages of the disease, thin-walled cysts of different sizes develop. In most patients, a combination of nodular and cystic parenchymal lesions is registered. Both nodules and cysts follow the apicobasal distribution, they are larger and more numerous in the upper than in the lower lung parts [8].

Spirometry tests can be normal in early stages (both LAM and PLCH patients), however as diseases progress airflow obstruction and decreased lung diffusion capacity occur [1]. Our patient with LAM had normal spirometry findings, while 6WMT distance was reduced. The PLCH patient had slightly decreased diffusion capacity. As far as pregnancy is concerned a study showed that it is safe in woman with PLCH and not associated with deterioration of pulmonary function or blood oxygenation [9]. The pregnancy and perinatal period in our patient went smoothly.

PLCH cells (Langerhans cells) are between 12-15  $\mu\text{m}$  in diameter, with eosinophilic cytoplasm. Immunohistochemical staining of these cells showed the expression of CD1a, S100 protein and CD207 (langerin) [10, 11, 12]. The characteristic finding consists of granulomas composed of the Langerhans cells described above and infiltrates of inflammatory cells (eosinophils, lymphocytes, neutrophils). Granulomas can occur in any organ (most common in the skin, bones, pituitary gland, liver and lungs).

Current therapy for LAM are mTOR inhibitors-sirolimus and everolimus [13]. Sirolimus is indicated in patients with  $\text{FEV1} \leq 70\%$ , chylous effusions or a rapidly progressive form of the disease [1]. The drug sirolimus is registered under the name Rapamune®, and everomilus under the name Afinitor® in the Republic of Serbia. In addition to mTOR inhibitors, supportive therapy in the form of bronchodilators and oxygen is recommended, as well as respiratory rehabilitation [3]. Regular immunization against the seasonal flu is necessary, as well as the application of pneumococcal vaccine. As far as lifestyle is concerned, smoking and diving are prohibited [1]. Since our patient was previously diagnosed with TSC, the decision on therapy (everolimus) was made in agreement with a neurologist and immunologist.

Smoking cessation plays a major role in the treatment of PLCH, leading to stabilization and even regression of the disease [14]. However, in one third of patients, the disease progresses even after smoking cessation. Numerous chemotherapeutic protocols have been tested so far, but with little success [14]. In our case smoking cessation led to slight radiological regression and ECHO improvement.

For both diseases pleurodesis is advised after the first episode of pneumothorax, and lung transplantation is indicated in the progressive form of the disease.


These diseases are extremely rare, far less frequently described in the literature compared to numerous other pulmonary diseases and should be distinguished from diseases that mimic lung cysts (emphysema, bronchiectasis, honeycomb lungs). A good cooperation of several specialists is necessary to establish the diagnose either of LAM or PHLIC.

**Conflict of interest:** None declared.

**REFERENCES**


1. Obaidat B, Yazdani D, Wikenheiser-Brokamp AK, Gupta N. Diffuse cystic lung diseases. *Respiratory Care*. 2020; 65(1):111-26. doi: 10.4187/respcare.07117
2. Park S, Lee EJ. Diagnosis and treatment of cystic lung disease. *Korean J Intern Med*. 2017;32:229-38. doi: 10.3904/kjim.2016.242
3. Lee KC, Kang EY, Yong HS, Kim C, Lee KY, Hwang HS, et al. A stepwise diagnostic approach to cystic lung diseases for radiologists. *Korean J Radiol*. 2019;20(9):1368-80. doi: 10.3348/kjr.2019.0057
4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol*. 2015;10(9):1243-60. doi: 10.1097/JTO.0000000000000630
5. Sreter KB, Barisic B, Light RW. Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy. *Lymphology*. 2017;50(4):183-7. PMID: 30248722
6. Milenković B, Bogdanović A, Cvok T, Mitić J, Stošić J, Dudvarski Ilić A. Plućna histiocitoza. *Med Pregl* 2013; LXVI (Suppl 1):101-105.
7. Xu KF, Xu W, Liu S, Yu J, Tian X, Yang Y, et al. Lymphangioleiomyomatosis. *Semin Respir Crit Care Med*. 2020;41:256-68. doi: 10.1055/s-0040-1702195
8. Galindo RG, Allen C. Langerhans cell histiocytosis. *Blood*. 2020;135(16):1319-31. doi: 10.1182/blood.2019000934
9. Radzikowska E. Update on Pulmonary Langerhans Cell Histiocytosis. 2021. *Front. Med*. 7:582581. doi: 10.3389/fmed.2020.582581
10. McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. *Lancet Respir Med*. 2021; 9(11):1313-27. doi: 10.1016/S2213-2600(21)00228-9
11. Srivatsav V, Tallon K. A unique presentation of Pulmonary Langerhans Cell Histiocytosis, *Respiratory Medicine Case Reports*, 2022, Vol 37, 101635, doi.org/10.1016/j.rmcr.2022.101635.
12. Kirk DJ. Pulmonary cystic disease and its mimics. *Int J Surg Pathol*. 2020;13:141-63. doi: 10.1016/j.path.2019.11.007
13. Landh E, Wang R, Lyn MM, Traini D, Young PM, Xin H. Ong. 2022 Prospective nanoparticle treatments for lymphangioleiomyomatosis, *Expert Opinion on Drug Delivery*, 19:1, 75-86, doi:10.1080/17425247.2022.2029401
14. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. *Blood*. 2020;135(16):1319-31. doi: 10.1182/blood.2019000934






**Figure 1.** Chest high-resolution computed tomography of the patient with lymphangiomyomatosis before therapy

Paper accepted




**Figure 2.** Chest high-resolution computed tomography of the patient with lymphangiomyomatosis after four years of therapy

Paper accepted



**Figure 3.** Initial chest high-resolution computed tomography of the patient with pulmonary Langerhans cell histiocytosis

Paper accepted



**Figure 4.** Chest high-resolution computed tomography of the patient with pulmonary Langerhans cell histiocytosis after three years

Paper accepted

**Table 1.** Findings of spirometry, diffusion capacity, and six-minute walk test at the first and control examination in a patient with lymphangioleiomyomatosis

|          | First examination |       | Control |       |
|----------|-------------------|-------|---------|-------|
|          | [l]               | %     | [l]     | %     |
| FVC      | 3.25              | 89.29 | 3.66    | 103.7 |
| FEV 1    | 2.75              | 87.58 | 2.93    | 96.38 |
| FEV1/FVC |                   | 84.62 |         | 80.05 |
| DLCO     | 7.61              | 82.09 | 6.35    | 69.93 |
| 6MWT     | 420m              | 57%   | 350m    | 47%   |

FVC – forced vital capacity; FEV1 – forced expiratory volume in one second; DLCO – diffusion capacity; 6MWT – six-minute walk test